AG˹ٷ

STOCK TITAN

HeartCore Reports First Quarter 2025 Financial Results

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

HeartCore Enterprises (NASDAQ: HTCR) reported its Q1 2025 financial results, showing significant challenges. Revenue decreased to $3.6 million from $5.0 million year-over-year, while net loss widened to $3.1 million from $1.5 million. The company's gross profit declined to $1.1 million from $2.0 million, though operating expenses improved 14% to $2.3 million.

The company's cash position weakened to $0.7 million as of March 31, 2025, down from $2.1 million at the end of 2024. Despite challenges, HeartCore announced strategic initiatives including a partnership with NEC Solutions Innovators, established a new business development team for its CMS business, and plans to expand its Go IPO consulting business into South Korea with a seminar scheduled for September 2025.

The decline in performance was attributed to decreased on-premise software revenue, reduced customized software development, and absence of new IPO consulting orders. The company's subsidiary Sigmaways showed improvement in cost reduction efforts.

HeartCore Enterprises (NASDAQ: HTCR) ha riportato i risultati finanziari del primo trimestre 2025, evidenziando sfide significative. I ricavi sono diminuiti a 3,6 milioni di dollari rispetto ai 5,0 milioni dell'anno precedente, mentre la perdita netta si è ampliata a 3,1 milioni di dollari da 1,5 milioni. Il margine lordo è calato a 1,1 milioni da 2,0 milioni, sebbene le spese operative siano migliorate del 14%, scendendo a 2,3 milioni.

La liquidità dell'azienda si è ridotta a 0,7 milioni di dollari al 31 marzo 2025, rispetto ai 2,1 milioni di fine 2024. Nonostante le difficoltà, HeartCore ha annunciato iniziative strategiche, tra cui una partnership con NEC Solutions Innovators, la creazione di un nuovo team per lo sviluppo del business nel settore CMS e l'espansione del servizio di consulenza Go IPO in Corea del Sud, con un seminario previsto per settembre 2025.

Il calo delle performance è stato attribuito alla diminuzione dei ricavi da software on-premise, alla riduzione dello sviluppo software personalizzato e all'assenza di nuovi ordini per la consulenza IPO. La controllata Sigmaways ha mostrato miglioramenti negli sforzi di riduzione dei costi.

HeartCore Enterprises (NASDAQ: HTCR) reportó sus resultados financieros del primer trimestre de 2025, mostrando desafíos significativos. Los ingresos disminuyeron a 3,6 millones de dólares desde 5,0 millones interanual, mientras que la pérdida neta se amplió a 3,1 millones de dólares desde 1,5 millones. La ganancia bruta de la empresa cayó a 1,1 millones desde 2,0 millones, aunque los gastos operativos mejoraron un 14%, situándose en 2,3 millones.

La posición de efectivo de la compañía se debilitó a 0,7 millones de dólares al 31 de marzo de 2025, desde 2,1 millones a finales de 2024. A pesar de los desafíos, HeartCore anunció iniciativas estratégicas que incluyen una asociación con NEC Solutions Innovators, la creación de un nuevo equipo de desarrollo comercial para su negocio CMS y planes para expandir su consultoría Go IPO en Corea del Sur con un seminario programado para septiembre de 2025.

La disminución en el desempeño se atribuyó a la reducción de ingresos por software on-premise, menor desarrollo de software personalizado y ausencia de nuevos pedidos de consultoría IPO. La subsidiaria Sigmaways mostró avances en la reducción de costos.

HeartCore Enterprises (NASDAQ: HTCR)� 2025� 1분기 재무 실적� 발표하며 상당� 어려움� 겪고 있음� 보였습니�. 매출은 전년 동기 대� 360� 달러� 감소했으�, 순손실은 310� 달러� 확대되었습니�. 회사� 총이익은 110� 달러� 감소했으�, 영업비용은 14% 개선되어 230� 달러� 기록했습니다.

2025� 3� 31� 기준 현금 보유액은 210� 달러에서 70� 달러� 감소했습니다. 어려움에도 불구하고 HeartCore� NEC Solutions Innovators와� 전략� 파트너십 체결, CMS 사업� 위한 신규 사업 개발팀 구성, 2025� 9� 예정� 세미나를 통한 한국 � Go IPO 컨설� 사업 확장 계획 � 전략� 이니셔티브를 발표했습니다.

실적 부진은 온프레미� 소프트웨� 매출 감소, 맞춤� 소프트웨� 개발 축소, 신규 IPO 컨설� 주문 부재에 기인합니�. 자회� Sigmaways� 비용 절감 노력에서 개선� 보였습니�.

HeartCore Enterprises (NASDAQ: HTCR) a publié ses résultats financiers du premier trimestre 2025, révélant des défis importants. Le chiffre d'affaires a diminué à 3,6 millions de dollars contre 5,0 millions d'une année sur l'autre, tandis que la perte nette s'est creusée à 3,1 millions de dollars contre 1,5 million. La marge brute de la société est passée de 2,0 millions à 1,1 million, bien que les frais d'exploitation aient été réduits de 14 % pour atteindre 2,3 millions.

La trésorerie de l'entreprise s'est affaiblie à 0,7 million de dollars au 31 mars 2025, contre 2,1 millions à la fin de 2024. Malgré ces difficultés, HeartCore a annoncé des initiatives stratégiques, notamment un partenariat avec NEC Solutions Innovators, la création d'une nouvelle équipe de développement commercial pour son activité CMS, et prévoit d'étendre son activité de conseil Go IPO en Corée du Sud avec un séminaire prévu en septembre 2025.

La baisse des performances a été attribuée à la diminution des revenus des logiciels sur site, à la réduction du développement de logiciels personnalisés et à l'absence de nouvelles commandes de conseil en IPO. La filiale Sigmaways a montré des progrès dans la réduction des coûts.

HeartCore Enterprises (NASDAQ: HTCR) meldete seine Finanzergebnisse für das erste Quartal 2025 und zeigte dabei erhebliche Herausforderungen. Der Umsatz sank im Jahresvergleich von 5,0 Millionen auf 3,6 Millionen US-Dollar, während der Nettoverlust sich von 1,5 Millionen auf 3,1 Millionen US-Dollar ausweitete. Der Bruttogewinn des Unternehmens fiel von 2,0 Millionen auf 1,1 Millionen, obwohl die Betriebskosten um 14 % auf 2,3 Millionen verbessert wurden.

Die Liquiditätslage des Unternehmens verschlechterte sich zum 31. März 2025 auf 0,7 Millionen US-Dollar, nach 2,1 Millionen Ende 2024. Trotz der Herausforderungen kündigte HeartCore strategische Initiativen an, darunter eine Partnerschaft mit NEC Solutions Innovators, die Gründung eines neuen Business-Development-Teams für das CMS-Geschäft und die geplante Expansion des Go-IPO-Beratungsgeschäfts nach Südkorea mit einem Seminar im September 2025.

Der Leistungsrückgang wurde auf sinkende Umsätze im On-Premise-Softwarebereich, reduzierte kundenspezifische Softwareentwicklung und das Ausbleiben neuer IPO-Beratungsaufträge zurückgeführt. Die Tochtergesellschaft Sigmaways zeigte Fortschritte bei Kostensenkungen.

Positive
  • None.
Negative
  • Revenue declined 28% YoY to $3.6 million
  • Net loss widened to $3.1 million from $1.5 million YoY
  • Gross profit decreased to $1.1 million from $2.0 million YoY
  • Cash and cash equivalents dropped to $0.7 million from $2.1 million in Q4 2024
  • No new IPO consulting orders received in Q1 2025
  • Balance sheet deficit due to decline in value of SBC Medical Group shares

Insights

HeartCore reports deteriorating financial performance with revenue down 28%, widening net losses, and rapidly diminishing cash reserves.

HeartCore's Q1 2025 results reveal concerning financial deterioration across multiple metrics. Revenue declined 28% year-over-year to $3.6 million, driven by weaknesses in three core segments: on-premise software, customized development services (via subsidiary Sigmaways), and their Go IPO consulting business, which notably secured zero new orders during the quarter.

The company's gross profit fell 45% to $1.1 million, indicating significant margin compression despite a 14% reduction in operating expenses. Most alarming is their cash position, which has plummeted 67% in just three months from $2.1 million (December 2024) to $0.7 million (March 2025). At the current cash burn rate, this raises serious liquidity concerns without immediate revenue improvement or capital injection.

The net loss more than doubled to $3.1 million compared to a $1.5 million loss in Q1 2024, and the adjusted EBITDA loss widened to $1.3 million from $0.3 million. Management attributes part of the balance sheet deficit to holding depreciated SBC Medical Group shares rather than operational issues, suggesting these assets could be liquidated if needed. The company is banking on revenue from clients expected to IPO in 2025 and expansion into South Korea, but with the company's South Korea seminar delayed to September 2025, these initiatives appear to be behind schedule.

While Sigmaways is narrowing losses, the overall trajectory remains negative, with no clear timeline for reversing the downward financial trend. The newly established business development team focused on CMS customer success may help with retention but doesn't address the immediate revenue and cash concerns facing the company.

NEW YORK and TOKYO, May 15, 2025 (GLOBE NEWSWIRE) -- HeartCore Enterprises, Inc. (Nasdaq: HTCR) (“HeartCore� or the “Company�), a leading enterprise software and consulting services company based in Tokyo, reported financial results for the first quarter ended March 31, 2025.

First Quarter 2025 and Recent Operational & Financial Highlights

  • strategic partnership with NEC Solutions Innovators, Ltd. to enhance CMS implementation process
  • new business development team aimed at strengthening customer success across HeartCore’s CMS business
  • plans to expand the Go IPO consulting business into South Korea. The Company adjusted its scheduled South Korea IPO seminar event to September 2025

Management Commentary
HeartCore CEO Sumitaka Kanno commented: “We continued to make meaningful strategic advancements across our software business this quarter, the cornerstone of HeartCore Enterprises. Building on the foundational improvements implemented last year, we launched a dedicated business development team this past quarter focused on strengthening customer success initiatives to better serve our CMS customers and maintain our strong retention rate. Our subsidiary Sigmaways has also made encouraging progress in reducing costs and has narrowed its losses compared to the same period last year. We will continue to closely monitor and prudently manage costs across Sigmaways� operations. The deficit on our balance sheet this quarter does not directly reflect the performance of our core business but is rather attributable to the SBC Medical Group shares we hold. The subsequent decline in their stock price has ultimately reduced the value of the assets held by HeartCore. Nevertheless, these shares continue to offer additional liquidity options if needed. Furthermore, a few of our Go IPO clients are expected to begin trading in 2025, which will in turn provide us with additional equity in these companies following their listings. With our upcoming South Korea IPO seminar scheduled for September, we are preparing our efforts to expand our footprint beyond Japan into new APAC regions. We look forward to announcing incremental updates across both businesses throughout the rest of the year.”�

First Quarter 2025 Financial Results
Revenues were $3.6 million compared to $5.0 million in the same period last year. The decrease was primarily due to decreased on-premise software revenue, decreased customized software development and services revenue attributed to the business slowdown of Sigmaways, and decreased Go IPO consulting services revenue as no new IPO consulting orders were entered this quarter.

Gross profit was $1.1 million compared to $2.0 million in the same period last year. The decrease was primarily due to a decrease of gross profit from on-premises software and Go IPO consulting services.

Operating expenses decreased 14% to $2.3 million, compared to $2.7 million in the same period last year. The improvement was primarily due to a decrease in general and administrative expenses.

Net loss was $3.1 million, compared to $1.5 million in the same period last year, as a result of the aforementioned decrease in revenue and gross profit for the quarter.

Adjusted EBITDA for the year totaled a loss of $1.3 million, compared to a loss of $0.3 million in the same period last year.

As of March 31, 2025, the Company had cash and cash equivalents of $0.7 million, compared to $2.1 million on December 31, 2024.

About HeartCore Enterprises, Inc.
Headquartered in Tokyo, Japan, HeartCore Enterprises is a leading enterprise software and consulting services company. HeartCore offers Software as a Service (SaaS) solutions to enterprise customers in Japan and worldwide. The Company also provides data analytics services that allow enterprise businesses to create tailored web experiences for their clients through best-in-class design. HeartCore’s customer experience management platform (CXM Platform) includes marketing, sales, service and content management systems, as well as other tools and integrations, which enable companies to enhance the customer experience and drive engagement. HeartCore also operates a digital transformation business that provides customers with robotics process automation, process mining and task mining to accelerate the digital transformation of enterprises. HeartCore’s GO IPOSM consulting services helps Japanese-based companies go public in the U.S. Additional information about the Company’s products and services is available at and .

Non-GAAP Financial Measures Disclaimer
This document includes references to adjusted EBITDA, which is a non-GAAP financial measure. For the purposes of this presentation, adjusted EBITDA is calculated by adjusting net loss to exclude depreciation and amortization, impairment of intangible asset, and impairment of goodwill.

This measure is presented as supplemental information and is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with U.S. GAAP.

Management believes that this adjusted EBITDA provides useful information to investors by highlighting the company’s core operational performance, excluding non-cash and non-recurring items. However, non-GAAP financial measures have limitations and should not be considered in isolation or as a substitute for financial results prepared in accordance with GAAP.

ItemFY25 Q1FY24 Q1
Net Loss-$3.1 million-$1.5 million
(+) Depreciation and amortization expense$0.0 million$0.2 million
(+) Changes in fair value of investments in marketable securities$1.8 million$0.2 million
(+) Changes in fair value of investment in warrants$0.1 million$0.7 million
(+) Interest income$0.0 million$0.0 million
(+) Interest expenses$0.0 million$0.0 million
Adjusted EBITDA-$1.3 million-$0.3 million


Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, or the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts included in this press release are forward-looking statements. In some cases, forward-looking statements can be identified by words such as “believed,� “intend,� “expect,� “anticipate,� “plan,� “potential,� “continue,� or similar expressions. Such forward-looking statements include risks and uncertainties, and there are important factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These factors, risks, and uncertainties are discussed in HeartCore’s filings with the Securities and Exchange Commission. Investors should not place any undue reliance on forward-looking statements since they involve known and unknown, uncertainties and other factors which are, in some cases, beyond HeartCore’s control which could, and likely will materially affect actual results, and levels of activity, performance, or achievements. Any forward-looking statement reflects HeartCore’s current views with respect to future events and is subject to these and other risks, uncertainties, and assumptions relating to operations, results of operations, growth strategy, and liquidity. HeartCore assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The contents of any website referenced in this press release are not incorporated by reference herein.

HeartCore Investor Relations Contact:
Gateway Group, Inc.
Matt Glover and John Yi
[email protected]
(949) 574-3860

HeartCore Enterprises, Inc.
Consolidated Balance Sheets
March 31,December 31,
20252024
(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents$738,984$2,121,089
Accounts receivable2,114,6551,950,050
Investments in marketable securities2,251,2764,495,703
Prepaid expenses537,970458,839
Current portion of long-term note receivable100,000100,000
Due from related party42,45340,139
Other current assets278,961251,545
Total current assets6,064,2999,417,365
Non-current assets:
Accounts receivable, non-current694,302752,930
Property and equipment, net438,243584,854
Operating lease right-of-use assets1,830,4861,936,097
Long-term investment in warrants526,165577,786
Long-term note receivable100,000100,000
Deferred tax assets115,802152,300
Security deposits325,441307,996
Long-term loan receivable from related party120,459123,928
Other non-current assets7,81011,778
Total non-current assets4,158,7084,547,669
Total assets$10,223,007$13,965,034
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Accounts payable and accrued expenses$1,839,759$2,039,323
Accounts payable and accrued expenses - related party22,81447,199
Accrued payroll and other employee costs517,436675,502
Due to related parties239932
Short-term debt134,689-
Short-term debt - related party75,00075,000
Current portion of long-term debts367,871401,255
Insurance premium financing127,56716,626
Factoring liability127,053172,394
Operating lease liabilities, current279,840371,951
Finance lease liabilities, current16,93215,956
Income tax payables739,450822,014
Deferred revenue1,437,2481,876,490
Other current liabilities1,009,373907,080
Total current liabilities6,695,2717,421,722
Non-current liabilities:
Long-term debts1,166,6781,238,813
Operating lease liabilities, non-current1,600,9771,614,996
Finance lease liabilities, non-current41,85443,593
Other non-current liabilities117,940183,895
Total non-current liabilities2,927,4493,081,297
Total liabilities9,622,72010,503,019
Shareholders' equity:
Preferred shares ($0.0001 par value, 20,000,000 shares authorized, no shares issued and outstanding as of March 31, 2025 and December 31, 2024)--
Common shares ($0.0001 par value, 200,000,000 shares authorized; 22,075,333 and 21,937,987 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively)2,2072,193
Subscription receivable-(103,942)
Additional paid-in capital20,835,86420,656,153
Accumulated deficit(19,331,835)(16,244,843)
Accumulated other comprehensive income334,685343,936
Total HeartCore Enterprises, Inc. shareholders' equity1,840,9214,653,497
Non-controlling interests(1,240,634)(1,191,482)
Total shareholders' equity600,2873,462,015
Total liabilities and shareholders' equity$10,223,007$13,965,034


HeartCore Enterprises, Inc.
Unaudited Consolidated Statements of Operations and Comprehensive Loss
For the three months ended March 31, For the three months ended March 31,
20252024
Revenues$3,587,026$5,046,732
Cost of revenues2,486,7423,014,543
Gross profit1,100,2842,032,189
Operating expenses:
Selling expenses291,160219,707
General and administrative expenses1,929,3882,406,303
Research and development expenses123,89389,134
Total operating expenses2,344,4412,715,144
Loss from operations(1,244,157)(682,955)
Other income (expenses):
Changes in fair value of investments in marketable securities(1,781,664)(234,082)
Changes in fair value of investment in warrants(51,621)(678,887)
Interest income3,0202,594
Interest expenses(29,133)(36,661)
Other income35,35997,016
Other expenses(12,549)(25,194)
Total other expenses(1,836,588)(875,214)
Loss before income tax expense (benefit)(3,080,745)(1,558,169)
Income tax expense (benefit)56,636(80,167)
Net loss(3,137,381)(1,478,002)
Less: net loss attributable to non-controlling interests(50,389)(144,652)
Net loss attributable to HeartCore Enterprises, Inc.$(3,086,992)$(1,333,350)
Other comprehensive income (loss):
Foreign currency translation adjustment(8,014)10,295
Total comprehensive loss(3,145,395)(1,467,707)
Less: comprehensive loss attributable to non-controlling interests(49,152)(149,563)
Comprehensive loss attributable to HeartCore Enterprises, Inc.$(3,096,243)$(1,318,144)
Net loss per common share attributable to HeartCore Enterprises, Inc.
Basic$(0.14)$(0.06)
Diluted$(0.14)$(0.06)
Weighted average common shares outstanding
Basic22,054,02920,854,714
Diluted22,054,02920,854,714


HeartCore Enterprises, Inc.
Unaudited Consolidated Statements of Cash Flows
For the three months ended March 31,For the three months ended March 31,
20252024
Cash flows from operating activities:
Net loss$(3,137,381)$(1,478,002)
Adjustments to reconcile net loss to net cash flows
used in operating activities:
Depreciation and amortization expenses26,907188,085
Loss on disposal of property and equipment117,305-
Amortization of debt issuance costs1,2221,173
Non-cash lease expense90,50893,133
Gain on termination of lease(9,059)(469)
Deferred income taxes43,932(80,780)
Stock-based compensation32,28091,712
Changes in fair value of investments in marketable securities1,781,664234,082
Changes in fair value of investment in warrants51,621678,887
Gain on settlement of asset retirement obligations(45,873)-
Changes in assets and liabilities:
Accounts receivable(14,678)(523,110)
Prepaid expenses78,792102,028
Other assets(13,759)(18,618)
Accounts payable and accrued expenses(219,830)295,799
Accounts payable and accrued expenses - related party(24,224)-
Accrued payroll and other employee costs(178,339)(149,603)
Due to related parties(702)(1,161)
Operating lease liabilities(84,948)(90,035)
Income tax payables(84,284)(2,387)
Deferred revenue(496,079)(300,011)
Other liabilities84,13460,658
Net cash flows used in operating activities(2,000,791)(898,619)
Cash flows from investing activities:
Net proceeds from sale of warrants-1,640,000
Proceeds from sale of marketable securities462,763-
Repayment of loan provided to related party10,29810,814
Net cash flows provided by investing activities473,0611,650,814
Cash flows from financing activities:
Payments for finance leases(4,071)(4,474)
Proceeds from short-term debt134,68968,138
Repayment of short-term and long-term debts(165,165)(207,486)
Repayment of insurance premium financing(28,559)(14,772)
Net repayment of factoring arrangement(45,341)(383,353)
Capital contribution from non-controlling shareholder-67,195
Proceeds from issuance of common shares30,445-
Proceeds from collection of subscription receivable103,942-
Proceeds from exercise of stock options117,000-
Net cash flows provide by (used in) financing activities142,940(474,752)
Effect of exchange rate changes2,685(70,671)
Net change in cash and cash equivalents(1,382,105)206,772
Cash and cash equivalents - beginning of the period2,121,0891,012,479
Cash and cash equivalents - end of the period$738,984$1,219,251
-
Supplemental cash flow disclosures:
Interest paid$22,857$37,098
Income taxes paid$93,586$117,524
Non-cash investing and financing transactions
Operating lease right-of-use assets obtained in exchange for operating lease liabilities$-$125,735
Insurance premium financing$139,500$172,689

FAQ

What were HeartCore's (HTCR) Q1 2025 revenue and net loss?

HeartCore reported Q1 2025 revenue of $3.6 million (down from $5.0 million YoY) and a net loss of $3.1 million (increased from $1.5 million YoY).

How much cash does HeartCore (HTCR) have as of March 2025?

HeartCore had cash and cash equivalents of $0.7 million as of March 31, 2025, down from $2.1 million at the end of December 2024.

What strategic initiatives did HeartCore (HTCR) announce in Q1 2025?

HeartCore announced a partnership with NEC Solutions Innovators, established a new business development team for CMS business, and plans to expand Go IPO consulting into South Korea with a September 2025 seminar.

Why did HeartCore's (HTCR) revenue decline in Q1 2025?

The revenue decline was due to decreased on-premise software revenue, reduced customized software development services, and no new IPO consulting orders during the quarter.

What is affecting HeartCore's (HTCR) balance sheet in Q1 2025?

The balance sheet deficit is primarily attributed to the decline in value of SBC Medical Group shares held by HeartCore.
HEARTCORE ENTERPRISES INC

NASDAQ:HTCR

HTCR Rankings

HTCR Latest News

HTCR Latest SEC Filings

HTCR Stock Data

12.14M
6.52M
75.35%
2.93%
0.11%
Software - Application
Services-computer Processing & Data Preparation
Japan
TOKYO